Molecular profiling of gastric cancer: Toward personalized cancer medicine

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 838-839

  Nadauld, Lincoln D ^a   Ford, James M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; UVOMORULIN;

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; DNA METHYLATION; EDITORIAL; EPIGENETICS; GENE; GENE DOSAGE; GENE EXPRESSION; GENE SILENCING; GENOME; HELICOBACTER PYLORI; HETEROZYGOSITY LOSS; HUMAN; MISMATCH REPAIR; MUTATION; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; STOMACH CANCER;

CADHERINS; DNA METHYLATION; FEMALE; GENE DELETION; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MUTATION; STOMACH NEOPLASMS;

EID: 84875717208     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.1714     Document Type: Editorial

References (17)

1. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
3. Chun N, Ford JM: Genetic testing by cancer site: Stomach. Cancer J 18:355-363, 2012.
4. Guilford P, Hopkins J, Harraway J, et al: E-cadherin germline mutations in familial gastric cancer. Nature 392:402-405, 1998.
5. Grady WM, Willis J, Guilford PJ, et al: Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26:16-17, 2000.
6. Machado JC, Oliveira C, Carvalho R, et al: E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20:1525-1528, 2001.
7. Corso G, Carvalho J, Marrelli D, et al: Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol 31:868-875, 2013.
8. Zouridis H, Deng N, Ivanova T, et al: Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med 4:156-140, 2012.
9. Lee J, van Hummelen P, Go C, et al: High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PloS One 7:e38892, 2012.
10. Wang K, Kan J, Yuen ST, et al: Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43:1219- 1223, 2011.
11. Zang ZJ, Cutcutache I, Poon SL, et al: Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44:570-574, 2012.
12. Dulak AM, Schumacher SE, van Lieshout J, et al: Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 72:4383-4393, 2012.
13. Kunz PL, Mojtahed A, Fisher GA, et al: HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: Clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 20:13-24, 2012.
14. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010.
15. Nadauld L, Regan JF, Miotke L, et al: Quantitative and sensitive detection of cancer genome amplifications from formalin fixed paraffin embedded tumors with droplet digital PCR. Transl Med 2:107, 2012.
16. Deng N, Goh LK, Wang H, et al: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673-684, 2012.
17. Yates LR, Campbell PJ: Evolution of the cancer genome. Nat Rev Genet 13:795-806, 2012.